Contraindicated (one)bortezomib will enhance the level or result of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or average CYP2C19 inhibitors might enhance mavacamten systemic publicity, resulting in heart failure due to systolic dysfunction. Lab and/or professional medical exams (which include complete blood rely) need to be completed if https://michaely211lvg3.estate-blog.com/profile